Etifoxine does not impair muscle tone and motor function in rats as assessed by in vivo and in vitro methods.

The purpose of our study is to evaluate the effects of the translocator protein (TSPO) ligand etifoxine on muscle tone and locomotor activity. In addition, the mechanism of action of etifoxine on the presynaptic membrane and neuromuscular junction is investigated. These effects of etifoxine were examined employing the following methods: 1) in vivo experiments using bar holding test and activity cage test, and 2) comparative in vitro studies with nifedipine on indirectly-elicited twitches of striated abdominal muscle preparations. Etifoxine in doses 50 mg/kg and 100 mg/kg i.p. does not produce any significant changes in locomotor activity and muscle tone of intact rats. Nifedipine (10-5 М) induces a significant decrease in the muscle force of striated muscle preparations. Etifoxine (10-8-10-4 М) has no significant effect on indirectly-elicited twitch tension. Results show that the TSPO ligand etifoxine has no myorelaxant effect. The activation of TSPO is not associated with a reduction in muscle tone and motor impairment. Etifoxine does not affect the presynaptic membrane and its influence on L-type Ca2+-channels is insignificant. Etifoxine does not act as a competitive antagonist of acetylcholine and does not impair the impulse transmission in the neuromuscular junction.

Effects of Low Level Laser Therapy on Erosive-atrophic Oral Lichen Planus.

BACKGROUND: The erosive-atrophic form of oral lichen planus (OLP) is associated with severe pain and burning sensation and is often unresponsive to treatment. Topical corticosteroids are considered as a medication of first choice but they can produce adverse effects. Therefore, new therapeutic approaches are required. AIM: The aim of this study was to investigate the effectiveness of biomodulation with diode laser in patients presenting with long-standing erosive-atrophic OLP. MATERIALS AND METHODS: Twelve patients, clinically and histologically diagnosed with OLP, participated in this study. The level of pain and the clinical scores of total 59 lesions were recorded before treatment using visual analog scale and Thongprasom sign scoring system respectively. All patients received low level laser therapy (LLLT) with diode laser (810 nm) with parameters (0.5 W, 30 s, 1.2 J/cm2) three times weekly for a month. The response rate was assessed according to the decrease in pain and sign scores. Treatment efficacy index was calculated. RESULTS: There was a significant reduction in pain after LLLT (p<0.0001). Improvement in clinical signs was achieved in 59.3% of the lesions. At the end of the treatment 5.1% of the lesions exhibited score 5; 6.8% - score 4, 11.9% of the lesions were scored 3 and 8.5% and 30.5% showed score 2 and score 1, respectively. Complete resolution was revealed in 37.3% of the lesions. All patients experienced some degree of improvement. Most of the cases showed moderate recovery. CONCLUSION: The present results indicate that LLLT is an effective and harmless modality for management of erosive-atrophic OLP.

Oral Lichen Planus - Known and Unknown: a Review.

Lichen planus is a chronic mucocutaneous inflammatory disease aff ecting 1-2% of the general population with maximum prevalence of the disease in women above the age of 40. Its aetiology remains unclear and the pathogenesis is still the object of much speculation. It is considered to be an autoimmune disorder mediated mainly by the T-lymphocytes. The present paper presents the most well-known external agents (viruses in particular), internal agents like stress, and the heat shock protein thought to be trigger factors and describes the action of diff erent cells and proteins associated with the development of that disease. Diagnosis is based on clinical and histopathologic evidence; direct and indirect immunofluorescence techniques can also be of use. Despite the wide variety of therapeutic modalities, treatment outcomes are often insufficient. Currently, topical corticosteroids are widely accepted as a standard therapy, but also retinoids, calcineurin inhibitors and other immunosuppressants can be administered. Because of the aspect relevant to these drugs, priority is given to alternative harmless methods such as LLLT and PDLT. There is an ongoing controversy in the literature about the possible premalignant character of oral lichen planus, however, periodic followup is recommended.

In Vitro Study of Temperature Changes in Pulp Chamber During Root Planing Procedure Using Er:YAG Laser.

AIM: To assess temperature changes at specified time intervals during Er:YAG laser scaling and root planing of surfaces with dental calculus. MATERIALS AND METHODS: Fifteen single-rooted teeth with advanced periodontal disease were extracted and fixed in a cylinder thermostat filled with distilled water at constant temperature (35.5°C). A specially designed thermal probe (type K thermocouple) accurate to ±0.1°C over the range from 20°C to 80°C was fitted into the pulp chamber of tooth sample. Scaling and root planing of the mesial and distal root surfaces was performed using an Er:YAG laser (Lite Touch, Syneron Dental, Israel) with a wavelength of 2940 nm, provided with a chisel tip, and at the following settings: output energy 100 mJ and 50 Hz, duration of irradiation - 40 sec, the tip in contact mode oblique to the root surface at an angle of approximately 10-15 degrees and water spray level 5-6. The temperature inside the pulp chamber was measured every 10 sec. RESULTS: The temperature in the pulp chamber taken every 10 seconds and compared with the temperature of 35.5°C at baseline decreased by 1.6°C, 2.4°C, 2.5°C, and 2.5°C for the first, second, third and fourth measurement, respectively. These changes did not reach statistical significance. CONCLUSION: The Er:YAG laser does not increase the temperature inside the pulp chamber. The assessed changes do not depend on the duration of irradiation which was kept within 40 seconds. Therefore, this treatment modality causes no thermal damage to the pulp under the above defined conditions and can be considered safe.

Formulation and performance evaluation of betahistine dihydrochloride microspheres as sustained release systems.

UNLABELLED: Betahistine dihydrochloride is a histamine-like drug widely used in relieving the symptoms associated with Ménière's syndrome. Pharmacokinetic studies of betahistine have demonstrated that it has a short plasma half-life of 3-4 hours. In such cases frequent administration of the drug is required in order to keep plasma concentration within the therapeutic range. However, this may lead to noncompliance and aggravate patients' comfort. An advanced approach for achieving sustained release of drugs is their incorporation in microparticulate carriers. AIM: To design a sustained release microsphere formulation of betahistine providing reduced dose frequency and lower risk of side effects occurrence. MATERIALS AND METHODS: Betahistine-loaded chitosan microspheres were obtained via W/O emulsion solvent evaporation technique and were characterized for particle size, drug loading and entrapment efficiency. Drug release into phosphate buffer saline pH 7.4 was performed and dissolution profiles of the formulations were obtained. To study the mechanism of drug release from the microspheres the dissolution data was fitted to various mathematic models. RESULTS: Betahistine-loaded microspheres were produced with a high drug loading and entrapment efficiency. The microcarriers were spherical in shape with mean particle size of 3.82 µm to 7.69 µm. Betahistine release studies from the microspheres showed similar and slightly increasing dissolution profiles. The drug release proceeded in a controlled manner following Fickian diffusion. CONCLUSION: The obtained results suggest that betahistine-loaded chitosan microspheres prepared by solvent evaporation method are capable of sustained release of drugs and therefore can be used as drug delivery systems in the treatment of Ménière's syndrome.